Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PROPOSED CASE LOG REVISIONS PER REVIEW COMMITTEE FOR DERMATOLOGY PROSPECTIVE TO JULY 1, 2014 Area Level 1: Perform Category Excision - Benign or Malignant Minimums 50 *Role(s) Surgeon Level 1: Perform Repair (Closure) Simple/Intermediate/Co mplex 50 Surgeon Level 2: Observe Mohs Micrographic Surgery 15 Surgeon + Observed Level 2: Observe Laser - Combined (Ablative, Non-ablative, Vascular) 15 Surgeon + Observed Level 2: Observe Botulinum Toxin Chemodeinnervation 10 Surgeon + Observed Level 2: Observe Soft Tissue Augmentation/Skin Fillers 5 Surgeon + Observed Level 2: Observe Flaps and Grafts (Split or Full) 13 Surgeon + Observed Level 2: Observe Nail Procedures 3 Surgeon + Observed *Surgeon + Observe - indicates that a resident may gain credit in this category minimum by either performing or observing. 1 ©2014 Accreditation Council for Graduate Medical Education (ACGME) LIST OF MEDICAL TOPICS FOR CASE LOG PROSPECTIVE TO JULY 2014 Log Each Encounter Immunobullous disease Connective tissue disease High Risk Systemic Medication Management Log Individual Patients Only Once Phototherapy Patch testing Indicate "Adult" or "Pediatric" Yes Yes Logged encounters should include only those patients with whom the resident plays an active role in diagnosis or management. “High Risk Systemic Medication Management” is the term the Committee has chosen to define patients who are on immunomodulating/immunosuppressive or molecular targeted medications. This does not include patients on isotretinoin or prednisone, as it is anticipated that these patients are commonly seen by all residents, and therefore logging these patients is unnecessary. Examples of high-risk systemic medications residents should log include: cyclosporine, methotrexate, acitretin, dapsone, mycophenolate mofetil, TNF antagonists, IL-12/23 antagonists, IL-17 antagonists, rituximab, thalidomide, lenalidomide, cyclophosphamide, daclizumab, ipilimumab, vemurafenib, vismodegib, and other new and emerging molecular-based therapies. Phototherapy patients include all NBUVB, BBUVB, PUVA, and UVA1 patients, but do not include those undergoing nonultraviolet light and laser-based technologies. Patch testing patients include patients evaluated for contact dermatitis and who undergo patch testing of any type, to include TRUE testing or more extensive patch testing. In order to log a patient, residents must be involved in the selection of the allergens to test for, and must interpret the patch test reactions in terms of reaction type and clinical relevance. 2 ©2014 Accreditation Council for Graduate Medical Education (ACGME)